We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-19.08%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
378
Reduced
937
Closed
183
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$6.27M |
| 2 |
TJX Companies
TJX
|
+$5.89M |
| 3 |
General Mills
GIS
|
+$5.87M |
| 4 |
HP
HPQ
|
+$5.84M |
| 5 |
Ford
F
|
+$5.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$16.7M |
| 2 |
Amazon
AMZN
|
+$14.9M |
| 3 |
Iron Mountain
IRM
|
+$14.6M |
| 4 |
Microsoft
MSFT
|
+$12.9M |
| 5 |
GDS Holdings
GDS
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.6% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Ambev
ABEV
$48.4B
| $71K | ﹤0.01% |
25,915
+9,688
| +60% | +$27.4K |
|
1227
Editas Medicine
EDIT
$402M
| $71K | ﹤0.01% |
1,682
-450
| -21% | -$25.6K |
|
|
BPMC
1228
DELISTED
Blueprint Medicines
BPMC
| $70K | ﹤0.01% |
724
-428
| -37% | -$42.7K |
|
1229
Kodiak Sciences
KOD
$2.52B
| $70K | ﹤0.01% |
613
-426
| -41% | -$58.2K |
|
|
MRSN
1230
DELISTED
Mersana Therapeutics
MRSN
| $70K | ﹤0.01% |
173
+3
| +2% | +$1.46K |
|
1231
Replimune Group
REPL
$449M
| $70K | ﹤0.01% |
2,288
-116
| -5% | -$4.34K |
|
|
VXRT
1232
DELISTED
Vaxart
VXRT
| $70K | ﹤0.01% |
11,566
-6,220
| -35% | -$47.8K |
|
|
NVTA
1233
DELISTED
Invitae Corporation
NVTA
| $70K | ﹤0.01% |
1,828
-502
| -22% | -$22.8K |
|
|
MRTX
1234
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $70K | ﹤0.01% |
408
-146
| -26% | -$28.9K |
|
|
ARNA
1235
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $70K | ﹤0.01% |
1,010
-896
| -47% | -$68.9K |
|
1236
America Movil
AMX
$77.2B
| $69K | ﹤0.01% |
5,061
+1,987
| +65% | +$27.3K |
|
1237
Denali Therapeutics
DNLI
$3.82B
| $69K | ﹤0.01% |
1,204
-452
| -27% | -$30.3K |
|
1238
Precision BioSciences
DTIL
$185M
| $69K | ﹤0.01% |
221
+103
| +87% | +$36.1K |
|
1239
Inovio Pharmaceuticals
INO
$84.7M
| $69K | ﹤0.01% |
619
-378
| -38% | -$49.7K |
|
1240
Iovance Biotherapeutics
IOVA
$2.1B
| $69K | ﹤0.01% |
2,187
-458
| -17% | -$19K |
|
1241
Novavax
NVAX
$1.21B
| $69K | ﹤0.01% |
380
-666
| -64% | -$133K |
|
1242
Ultragenyx Pharmaceutical
RARE
$2.56B
| $69K | ﹤0.01% |
609
-296
| -33% | -$40.3K |
|
|
CCXI
1243
DELISTED
ChemoCentryx, Inc.
CCXI
| $69K | ﹤0.01% |
1,351
-908
| -40% | -$54.6K |
|
1244
BridgeBio Pharma
BBIO
$16.8B
| $68K | ﹤0.01% |
1,103
-1,044
| -49% | -$68.3K |
|
1245
Fate Therapeutics
FATE
$270M
| $68K | ﹤0.01% |
822
-576
| -41% | -$55.2K |
|
|
IGMS
1246
DELISTED
IGM Biosciences
IGMS
| $68K | ﹤0.01% |
890
+6
| +0.7% | +$546 |
|
1247
Insmed
INSM
$22.6B
| $68K | ﹤0.01% |
1,990
-1,328
| -40% | -$50.8K |
|
1248
Relay Therapeutics
RLAY
$3.99B
| $68K | ﹤0.01% |
1,981
+432
| +28% | +$18.7K |
|
1249
Twist Bioscience
TWST
$5.51B
| $68K | ﹤0.01% |
546
-382
| -41% | -$58K |
|
1250
Karyopharm Therapeutics
KPTI
$161M
| $67K | ﹤0.01% |
422
-135
| -24% | -$28.4K |
|
Similar funds
SAM
Pacer Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Pacer Advisors held 1,587 positions worth $5.75B, up 8.1% from $5.32B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pacer Advisors withdrew a net $1.1B in Q1 2021, closing 183 positions and reducing 937 holdings. Its most notable exit was Rithm Capital, an estimated $4.39M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pacer Advisors opened a new position in Aerojet Rocketdyne Holdings worth $3.39M.
- Pacer Advisors's largest Q1 2021 buy was Aerojet Rocketdyne Holdings: 72,150 shares worth $3.39M.
- Pacer Advisors added most to Newmont in Q1 2021, an estimated $6.27M increase.
- Pacer Advisors's biggest Q1 2021 reduction was Apple, cutting an estimated $16.7M.
- Pacer Advisors fully exited Rithm Capital in Q1 2021, selling an estimated $4.39M.
- Pacer Advisors's ten largest holdings make up 27% of its $5.75B portfolio in Q1 2021.
- Pacer Advisors opened 76 new positions and closed 183 in Q1 2021.
- Pacer Advisors's portfolio value rose 8.1% quarter-over-quarter to $5.75B.
Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.